{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T05:46:40Z","timestamp":1795240000764,"version":"4.10.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016226","name":"Accuray","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.radonc.2020.10.031","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T21:27:53Z","timestamp":1603488473000},"page":"138-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1067-2663","authenticated-orcid":false,"given":"William R.","family":"Grubb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ponsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9766-2056","authenticated-orcid":false,"given":"Michael","family":"Kharouta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Traughber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Sandstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eswar","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Machtay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2020.10.031_b0005","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.radonc.2020.10.031_b0010","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2020.10.031_b0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.euo.2018.08.023","article-title":"Clinical stage migration and survival for renal cell carcinoma in the United States","volume":"2","author":"Patel","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.eururo.2015.02.001","article-title":"Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry","volume":"68","author":"Pierorazio","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.10.031_b0025","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.6004\/jnccn.2019.0054","article-title":"NCCN Guidelines insights: kidney cancer, version 2.2020","volume":"17","author":"Motzer","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.radonc.2020.10.031_b0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2017.04.100","article-title":"Renal mass and localized renal cancer: AUA guideline","volume":"198","author":"Campbell","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2020.10.031_b0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2018.03.011","article-title":"Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and >5-yr clinical outcomes","volume":"74","author":"McIntosh","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.10.031_b0040","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/cncr.24035","article-title":"Radical versus partial nephrectomy: effect on overall and noncancer mortality","volume":"115","author":"Zini","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.10.031_b0045","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.3390\/cancers3044010","article-title":"Role of radiation therapy in the management of renal cell cancer","volume":"3","author":"Blanco","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2020.10.031_b0050","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ijrobp.2009.02.089","article-title":"Radiation-associated kidney injury","volume":"76","author":"Dawson","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.10.031_b0055","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","article-title":"Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model","volume":"50","author":"Walsh","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2020.10.031_b0060","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0090-4295(02)02442-1","article-title":"Initial evaluation of Cyberknife technology for extracorporeal renal tissue ablation","volume":"61","author":"Ponsky","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2020.10.031_b0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0070","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-018-0992-3","article-title":"A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma","volume":"13","author":"Correa","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2013.06.218","article-title":"A phase I dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma","volume":"87","author":"McBride","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.10.031_b0085","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2020.10.031_b0090","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2020.10.031_b0095","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/1553350607310546","article-title":"Renal radiosurgery: initial clinical experience with histological evaluation","volume":"14","author":"Ponsky","year":"2007","journal-title":"Surg Innov"},{"key":"10.1016\/j.radonc.2020.10.031_b0100","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.radonc.2020.10.031_b0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0110","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/cncr.20539","article-title":"Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study","volume":"101","author":"Onishi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2020.10.031_b0115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamaoncol.2018.6993","article-title":"Measuring the integration of stereotactic ablative radiotherapy plus surgery for early-stage non-small cell lung cancer: a phase 2 clinical trial","volume":"5","author":"Palma","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","article-title":"Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study","volume":"75","author":"Fakiris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.10.031_b0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG Oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jamaoncol.2018.1258","article-title":"Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2020.10.031_b0135","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2020.10.031_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053158","article-title":"Evaluation of ghost cell survival in the area of radiofrequency ablation","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS ONE"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020308781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814020308781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:14:14Z","timestamp":1759122854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814020308781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":28,"alternative-id":["S0167814020308781"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2020.10.031","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2020.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}